Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation

BACKGROUND: Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of hemorrhage. We sought to determine the cost-effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Soyon, Mullin, Rachel, Blazawski, Jon, Coleman, Craig I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467203/
https://www.ncbi.nlm.nih.gov/pubmed/23056642
http://dx.doi.org/10.1371/journal.pone.0047473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467203/
https://www.ncbi.nlm.nih.gov/pubmed/23056642
http://dx.doi.org/10.1371/journal.pone.0047473

Ejemplares similares